Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

$40m-$99.9m

Arrakis arranges $75m series B
Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.
Gen.G generates $46m round
Stanford University has participated in a $46m funding round for Gen.G together with venture capital firms and celebrity investors such as actor Will Smith.
Investors load up Astroscale series D to $80m
The space debris removal company has raised another $30m for its series D round from investors including UTokyo Innovation Platform and has now received $132m in total.
Inozyme hardens up with $67m
Novo and Sanofi Ventures returned to reinvest in Yale spinout Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.
HistoSonics sounds out corporates to raise $54m
Varian Medical Systems led University of Michigan's robotic-assisted ultrasound device spinout's series C round, which also included Johnson & Johnson Innovation - JJDC.
Inivata invites investors to series B
IP Group, CIC and Johnson & Johnson have returned for a $52.2m series B round in Inivata, a spinout of Cancer Research UK and University of Cambridge.
Surrozen generates $50m series B
Based on Stanford research, Surrozen is working on regenerative treatments for a wide range of conditions, with a first focus on liver disease.
Mojo Vision sets $58m series B scene
Stanford-StartX has contributed to a $58m series B for AR platform Mojo Vision, which also attracted Google, HP, Motorola Solutions, LG and Kakao.

Other News

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Aprea prolongs series C to $62.8m
Karolinska Institute’s oncology spinout Aprea Therapeutics has received a $5.7m series C extension adding to an initial $56.8m close in November 2018 that featured Karolinska Development.
Motif Ingredients structures $90m series A
MIT spinout Ginkgo Bioworks has set up Motif Ingredients with $90m in series A funding provided by investors including Louis Dreyfus Company and Fonterra.
Vor roars to $42m series A
Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.
Nuvaira shares $79m series E news
Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.
Spin Memory banks Abies for series B
NYU and Allied Minds-founded Ram technology developer Spin Memory has unveiled deep tech-focused VC firm Abies Ventures as an investor in a $52m series B first announced late last year.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg

Login